Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

819 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Prenatal diagnosis of Thailand deletion of α-thalassemia 1 families].
Lin N, Lin Y, Huang HL, Lin XL, He DQ, He SQ, Guo DH, Li Y, Xu LP. Lin N, et al. Among authors: xu lp. Zhonghua Yi Xue Za Zhi. 2016 Jun 28;96(24):1919-22. doi: 10.3760/cma.j.issn.0376-2491.2016.24.010. Zhonghua Yi Xue Za Zhi. 2016. PMID: 27373361 Chinese.
[Clinical value of PCR for viral detection of bronchoalveolar lavage fluid in the diagnosis and treatment of pneumonia after allogeneic hematopoietic stem cell transplantation].
Chen YY, Luo XY, Zhao XS, Jiang ZH, Chen Y, Chen H, Mo XD, Han W, Wang FR, Wang JZ, Yan CH, Sun YQ, Zhang YY, Han TT, Tang FF, Fu HX, Zhang S, Wang Y, Xu LP, Zhang XH, Liu KY, Huang XJ. Chen YY, et al. Among authors: xu lp. Zhonghua Xue Ye Xue Za Zhi. 2017 Nov 14;38(11):934-939. doi: 10.3760/cma.j.issn.0253-2727.2017.11.006. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 29224314 Free PMC article. Chinese.
[Clinical analysis of hereditary coagulation factor Ⅴ deficiency].
Zhang Y, Zhao JZ, Jiang Q, Jiang H, Lu J, Fu HX, Lü M, Xu LP, Zhang XH. Zhang Y, et al. Among authors: xu lp. Zhonghua Yi Xue Za Zhi. 2018 Sep 25;98(36):2920-2924. doi: 10.3760/cma.j.issn.0376-2491.2018.36.009. Zhonghua Yi Xue Za Zhi. 2018. PMID: 30293350 Chinese.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
[Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
Wang XY, Chang YJ, Liu YR, Qin YQ, Xu LP, Wang Y, Zhang XH, Yan CH, Sun YQ, Huang XJ, Zhao XS. Wang XY, et al. Among authors: xu lp. Zhonghua Xue Ye Xue Za Zhi. 2021 Feb 14;42(2):116-123. doi: 10.3760/cma.j.issn.0253-2727.2021.02.005. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 33858041 Free PMC article. Chinese.
819 results